Advertisement
Product › Details
Lyxumia® (Adlyxin™)
Next higher product group | lixisenatide | |
Status | 2011-11-01 registration filed | |
Organisation | Sanofi S.A. (Euronext: SAN, Nasdaq: SNY) | |
Group | Sanofi (Group) [since May 2011] | |
Organisation 2 | Zealand Pharma A/S (Nasdaq: ZEAL) | |
Group | Zealand Pharma (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for GLP-1 receptor agonist
- [1] Roche. (12/4/23). "Press Release: Roche Enters into a Definitive Merger Agreement to Acquire Carmot Therapeutics, including Three Clinical Stage Assets with Best-in-class Potential in Obesity and Diabetes". Basel....
- [2] AstraZeneca plc. (11/9/23). "Press Release: AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity [This press release is intended for investors and business / science media]"....
- [3] Novo Nordisk A/S. (8/16/17). "Press Release: Semaglutide Superior to Dulaglutide on Glucose Control and Weight Loss in People with Type 2 Diabetes in SUSTAIN 7". Bagsværd....
- [4] Sanofi S.A.. (1/4/17). "Press Release: Sanofi Announces Soliqua 100/33 Now Available in the U.S.". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top